• Earlier in March 2026, Element U.S. Space & Defense announced a collaboration with Leonardo DRS to install a semi-anechoic electromagnetic interference chamber at Leonardo DRS’s Menomonee Falls, WI facility, aiming to expand high-power EMI testing capacity for U.S. Navy systems from the first quarter of 2026.
• The partnership is expected to create one of the most advanced EMI test facilities in the U.S., potentially tightening Leonardo DRS’s role in validating mission-critical naval power systems under real-world electromagnetic conditions and supporting faster development and delivery cycles.
• Next, we’ll examine how this advanced EMI testing collaboration with Element could influence Leonardo DRS’s investment narrative around naval modernization.

The future of work is here. Discover the 32 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

Leonardo DRS Investment Narrative Recap

To own Leonardo DRS, you need to believe in sustained demand for advanced defense electronics, particularly in U.S. naval modernization, and in the company’s ability to convert its record backlog into profitable growth. The new EMI test chamber with Element could support that story by strengthening DRS’s position in high power naval systems testing, but it does not, by itself, remove the near term reliance on concentrated U.S. government contracts or exposure to higher R&D and input costs.

Among recent announcements, the appointment of Reuben Jeffery III to the board is especially relevant here. His background in public policy, global finance, and governance could be valuable as DRS deepens its U.S. Navy ties and manages complex, long duration programs like those that will use the new EMI facility. For investors watching catalysts around naval programs and defense budgets, this added governance experience may matter as much as the technical collaboration itself.

Yet against this positive backdrop, investors still need to weigh the risk that heavy dependence on large U.S. defense programs could...

Leonardo DRS' narrative projects $4.1 billion revenue and $351.1 million earnings by 2028. This requires 6.6% yearly revenue growth and about a $101 million earnings increase from $250.0 million today.

Uncover how Leonardo DRS' forecasts yield a $50.90 fair value, a 16% upside to its current price.

Exploring Other Perspectives

While consensus sees steady growth, the most cautious analysts, who expected revenue of about US$4.0 billion and earnings near US$356 million by 2028, worry that rising ESG scrutiny and defense budget pressure could limit how much benefit DRS ultimately captures from moves like its advanced EMI testing partnership, so it is worth comparing these more pessimistic views with your own expectations.

Explore 6 other fair value estimates on Leonardo DRS - why the stock might be worth as much as 26% more than the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Leonardo DRS research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Leonardo DRS research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Leonardo DRS' overall financial health at a glance.

Curious About Other Options?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• Uncover the next big thing with 33 elite penny stocks that balance risk and reward.
• AI is about to change healthcare. These 36 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Capitalize on the AI infrastructure supercycle with our selection of the 34 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.